Healthcare Mega-Deals 2024-2026: The Transactions Every Candidate Must Know

Introduction

Healthcare M&A is in the midst of a historically active period. Global biotech deal value reached approximately $228 billion in 2025, up 73% from $132 billion in 2024, making it the strongest M&A year since 2019 by several measures. Overall pharma M&A deal value rose 31% year-over-year to $179.6 billion, underpinned by 11 megadeals (transactions valued above $5 billion) compared to just three in 2024. Global health industries M&A values rose 46% in 2025 despite a 5% decline in deal volume, indicating a clear shift toward larger, more transformative transactions. The activity is not random: it is driven by a convergent set of structural forces, primarily the **$236 billion** patent cliff, the GLP-1 revolution reshaping metabolic disease, PE activity in healthcare services, and the return of large-cap acquirers with clean balance sheets and urgent pipeline needs. For interview candidates, knowing these deals by heart, and more importantly, being able to articulate the strategic rationale behind each one, is non-negotiable. Interviewers at healthcare-focused banks will ask "what deal are you following?" and expect a response that demonstrates analytical depth, not just awareness that a transaction occurred.

This article analyzes the most important healthcare transactions of 2024-2026, organized by the strategic theme that drove each deal.

The largest driver of biopharma M&A is the impending loss of exclusivity for blockbuster drugs. Pharma companies facing patent cliffs must acquire pipeline assets to replace revenue they know they will lose. These deals are characterized by urgency (the buyer's timeline is set by LOE dates), premium pricing (asset scarcity drives competition among multiple potential acquirers), and contingent consideration (bridging valuation gaps with CVRs and milestones).

Pfizer / Seagen ($43 Billion, 2023)

The landmark transaction of the current M&A cycle. Pfizer acquired Seagen, the leading antibody-drug conjugate company, for $43 billion in an all-cash deal. The strategic rationale was straightforward: Pfizer faced an acute revenue cliff from declining COVID franchise revenue and needed a transformative oncology platform. Seagen's four approved ADCs (Adcetris, Padcev, Tukysa, Tivdak) provided immediate revenue, and its ADC technology platform offered a pipeline of next-generation programs.

J&J / Intra-Cellular Therapies ($14.6 Billion, 2025)

Johnson & Johnson acquired Intra-Cellular Therapies to strengthen its neuroscience portfolio. Intra-Cellular's lead product, Caplyta (lumateperone), was approved for schizophrenia and bipolar depression and was generating rapidly growing revenue with significant expansion potential. The deal reflected a broader 2025 trend: CNS/neurology overtook oncology as the largest therapeutic area by M&A value, capturing $30.7 billion in deal value versus $23.5 billion for oncology.

The CNS Renaissance in Biopharma M&A

After years in which oncology dominated biopharma M&A (representing 40-50% of total deal value in most years), 2025 marked a turning point as neuroscience emerged as the largest therapeutic area by acquisition value. This shift was driven by multiple factors: new scientific understanding of neurological disease mechanisms (particularly in schizophrenia, depression, and neurodegeneration), the approval of breakthrough therapies that validated new targets, and the recognition by large pharma companies that CNS represents one of the last large therapeutic categories where significant unmet need exists and competition is relatively limited. The J&J/Intra-Cellular and AbbVie/Cerevel transactions were the two largest manifestations of this trend, but dozens of smaller neuroscience deals contributed to the overall shift. For healthcare banking candidates, the CNS renaissance is a key theme to understand because it signals a structural broadening of M&A demand beyond the oncology concentration that defined the prior decade.

Merck / Cidara Therapeutics ($9.2 Billion, 2025)

Merck's acquisition of Cidara Therapeutics for approximately $9.2 billion targeted Cidara's late-stage influenza antiviral candidate CD388. The deal highlighted Merck's diversification strategy beyond oncology (where Keytruda's LOE exposure creates $29 billion+ in revenue at risk) into infectious disease, a therapeutic area with large patient populations and favorable reimbursement dynamics. The Cidara deal also demonstrated the emerging willingness of acquirers to pay blockbuster premiums for assets in therapeutic areas that had been underinvested during the decade-long oncology dominance of biopharma M&A. Infectious disease, respiratory, and immunology assets have seen valuation re-ratings as acquirers seek diversification beyond the increasingly crowded oncology landscape.

Novartis / Avidity Biosciences ($12 Billion, 2025)

Novartis acquired RNA therapeutics developer Avidity Biosciences for approximately $12 billion, securing Avidity's antibody-oligonucleotide conjugate (AOC) platform. The deal reflected the growing conviction that RNA-based therapeutics represent the next major modality platform after antibodies and ADCs. Avidity's technology enables targeted delivery of RNA therapeutics to muscle tissue, with lead programs in myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. For Novartis, the acquisition filled a gap in its modality portfolio and positioned it in the emerging RNA therapeutics space alongside Alnylam (RNAi) and Ionis (antisense oligonucleotides).

Sanofi / Blueprint Medicines ($9.1 Billion, 2025)

Sanofi's acquisition of Blueprint Medicines for $9.1 billion added a precision oncology and allergy platform anchored by Ayvakit (avapritinib) for systemic mastocytosis. The deal was notable because Blueprint's commercial-stage product provided immediate revenue contribution while its pipeline offered multiple expansion opportunities. Together with J&J/Intra-Cellular and Merck/Cidara, the Sanofi/Blueprint deal was one of the three mega-transactions that accounted for roughly half of 2025's total biopharma deal value.

AbbVie / Cerevel Therapeutics ($8.7 Billion, 2024)

AbbVie's acquisition of Cerevel for $8.7 billion added a neuroscience pipeline anchored by emraclidine (a muscarinic receptor agonist for schizophrenia) and tavapadon (for Parkinson's disease). The deal demonstrated that Big Pharma is willing to pay substantial premiums for Phase II assets in high-unmet-need therapeutic areas, particularly when the buyer has existing commercial infrastructure in the therapeutic area.

The GLP-1 revolution has triggered a wave of M&A as companies race to establish positions in the obesity and cardiometabolic markets.

Pfizer / Metsera ($10 Billion, 2025)

Pfizer acquired Metsera, a clinical-stage biotech developing long-acting GLP-1 receptor agonists, for $10 billion after a reported bidding war with Novo Nordisk. The deal highlighted the strategic urgency in GLP-1: Pfizer's internal oral GLP-1 program (danuglipron) had experienced clinical setbacks, and Metsera's differentiated delivery system (designed for monthly or less frequent dosing) offered a potentially best-in-class profile that could differentiate Pfizer in a market projected to reach $130-200 billion+.

Novo Nordisk / Akero Therapeutics ($5.2 Billion, 2025)

Novo Nordisk's acquisition of Akero for up to $5.2 billion expanded its metabolic disease portfolio beyond GLP-1 into MASH (metabolic dysfunction-associated steatohepatitis), a liver disease with significant unmet need and a large potential market. The deal showed Novo's strategy of leveraging its metabolic disease commercial infrastructure to build a broader cardiometabolic franchise.

Novo Holdings / Catalent ($16.5 Billion, 2024)

The Novo/Catalent transaction deserves its own discussion because it was not a typical pipeline acquisition. Novo Holdings (Novo Nordisk's parent company) acquired Catalent, a diversified CDMO, for $16.5 billion primarily to secure three fill-finish manufacturing facilities for semaglutide production. This was a vertical integration play driven by manufacturing capacity constraints: Novo Nordisk was losing billions in potential revenue because it could not produce enough semaglutide to meet demand. The deal illustrates how modality-specific capacity constraints can drive CDMO valuations to strategic premiums far above standalone financial analysis.

J&J / Shockwave Medical ($13.1 Billion, 2024)

J&J's acquisition of Shockwave Medical for $13.1 billion secured intravascular lithotripsy (IVL) technology, which uses sonic pressure waves to treat calcified arterial disease. The strategic rationale was both offensive (adding a high-growth device category to J&J's cardiovascular portfolio) and defensive (preventing competitors from acquiring the technology). Shockwave's IVL platform was expanding from peripheral artery applications into the larger coronary artery market, creating a revenue growth trajectory that justified the premium valuation.

Intravascular Lithotripsy (IVL)

A catheter-based technology that uses sonic pressure waves (similar to kidney stone lithotripsy) to crack calcified plaque in arteries, restoring vessel compliance and enabling stent deployment in heavily calcified lesions that are difficult to treat with conventional balloon angioplasty. Shockwave Medical pioneered this approach and was the sole commercial provider at the time of J&J's acquisition, creating a competitive moat that justified the $13.1 billion price tag.

Abbott / Exact Sciences ($23 Billion, 2025)

Abbott announced the acquisition of molecular diagnostics company Exact Sciences for approximately $23 billion in November 2025, making it one of the largest device/diagnostics deals in history. Exact Sciences' Cologuard franchise (non-invasive colorectal cancer screening) represents a high-growth, high-margin consumables business with massive installed base expansion potential as CMS screening guidelines expand the eligible population. For Abbott, the deal adds a leading position in cancer screening diagnostics to its existing core lab and point-of-care testing platforms. The strategic logic follows the tools/diagnostics playbook: acquiring a consumables-driven, recurring-revenue business with spec-in protection and long-term growth visibility.

Blackstone-TPG / Hologic ($18.3 Billion, 2025)

In one of the largest PE-led healthcare transactions of the cycle, Blackstone and TPG jointly agreed to acquire women's health company Hologic for $18.3 billion in October 2025. Hologic's portfolio spans breast and cervical cancer screening, surgical products, and diagnostics. The deal is significant for multiple reasons: it demonstrates PE appetite for large-cap medtech acquisitions (not just healthcare services), the consortium structure reflects the deal size exceeding any single firm's typical check size, and Hologic's recurring revenue profile from diagnostic consumables and surgical instruments provides the predictable cash flows PE firms seek. The Hologic deal, combined with Abbott/Exact Sciences, signals that diagnostics and screening are emerging as a premium M&A category alongside traditional device innovation.

The 2026 M&A pipeline is expected to be among the most active in healthcare history. Several dynamics are building.

Merck/Revolution Medicines. As of early 2026, Merck is reportedly in talks to acquire Revolution Medicines for as much as $32 billion, which would make it the largest biotech acquisition since Pfizer/Seagen and one of the top five biopharma deals ever. Revolution's RAS(ON) inhibitor platform targets some of the most common oncology mutations (KRAS, NRAS, HRAS), addressing a target class that was previously considered "undruggable." The deal would help Merck diversify beyond Keytruda as it approaches LOE while securing a potentially transformative oncology franchise.

Continued patent cliff urgency. With **$236 billion** in branded drug revenue facing LOE through 2030, and roughly 190 drugs (including 69 blockbusters) losing market exclusivity during this period, the acquisition imperative only intensifies. Companies that have not yet made pipeline-replenishing acquisitions face growing pressure from investors and analysts. Goldman Sachs has predicted a record-breaking year for pharma and biotech M&A in 2026, with industry analysts projecting 20+ acquisitions above $1 billion.

PE services activity. Beyond biopharma, healthcare services M&A continues at elevated levels, with PE accounting for 42%+ of middle-market deal volume through platform and add-on strategies. However, healthcare provider M&A was muted overall in 2025, with dealmakers shifting toward mid-market and distress-driven transactions, reflecting tight margins, labor pressures, and heightened FTC antitrust scrutiny. The contrast between booming biopharma M&A and notably more cautious healthcare services dealmaking is a dynamic that candidates should be prepared to discuss in interviews.

Medtech consolidation. The Abbott/Exact Sciences and Blackstone-TPG/Hologic deals in Q4 2025 may signal the beginning of a medtech M&A wave comparable to what biopharma experienced in 2024-2025. Large medtech companies face their own version of the growth challenge: maturing product lines, pricing pressure from hospital GPOs, and competition from emerging technology platforms. Acquiring high-growth diagnostics, robotic surgery, and digital health assets offers a path to re-accelerate organic growth.

The next article covers the GLP-1 revolution and how obesity drugs are reshaping healthcare investment banking across every sub-sector.